Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone
James Croft(Institute of Cancer Research), Martin Kaiser(Royal Marsden NHS Foundation Trust), Anjan Thakurta(University of Oxford), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gordon Cook(University of Leeds), Debbie Sherratt(University of Leeds), Sarah Brown(University of Leeds), Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Katrina Walker(University of Leeds), William E. Pierceall(Bristol-Myers Squibb (Switzerland)), Andrew Hall(University of Leeds), Amy L. Sherborne(Institute of Cancer Research), Sadie Reed, Kevin Boyd(Royal Marsden Hospital)
Cited by 8
Related Papers
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564